CoronaryAtlas logo
CoronaryAtlas
cfDNA
Pathway / Myocardial injury (shared endpoint)

cfDNA

other

Cell-free DNA released from necrotic myocardium, reflecting infarct size and severity in acute myocardial infarction.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleCell-free DNA released during cardiomyocyte necrosis; AMI severity marker.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
63
C — confounder / Type-II
80
A — assay feasibility
45
E — evidence strength
31
T1DI (composite)
6
Specificity differential (R−C)-16.8
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Method depends on analyte chemistry
Reagent / substrate
Analyte-specific
Platform
Variable
Turnaround · availability
Research · Research

Literature evidence(2)